Articles: neuralgia.
-
J Pain Symptom Manage · Oct 1995
Clinical TrialLong-term intraspinal infusions of opioids in the treatment of neuropathic pain.
Long-term intraspinal infusions of opioid drugs are being increasingly utilized in patients with noncancer pain. Despite this, there is a lack of long-term information, including success and failure rates for pain relief and technical problems. During a 5-year period, 18 noncancer patients underwent implantation of programmable infusion pumps for long-term intrathecal opioid infusion. ⋯ Failure of long-term pain relief occurred in 39% (7/18) despite good pain relief in trial infusions and the use of both morphine and sufentanil. Technical problems developed in 6/18 patients but appeared to be preventable with further experience. Long-term intrathecal opioid infusions can be effective in treatment of neuropathic pain but might require higher infusion doses.
-
J Pain Symptom Manage · Oct 1995
Case ReportsLong-term ketamine subcutaneous continuous infusion in neuropathic cancer pain.
Neuropathic cancer pain may be less responsive to opioids than other pain. Several studies suggest that N-methyl-D-aspartate (NMDA)-receptor antagonists could play a role in the treatment of neuropathic pain. Ketamine is an NMDA-receptor antagonist that is used as an anesthetic and has been suggested as a useful drug for neuropathic pain. ⋯ We describe a patient who developed neuropathic cancer pain unresponsive to opioid escalation and spinal administration of a combination of bupivacaine-morphine and was subsequently treated by subcutaneous continuous ketamine infusion. A starting dose of 150 mg/day provided good pain relief and a dramatic reduction of the oral morphine dose (from 5 g to 200 mg). A slow and progressive increase of ketamine and morphine dosage (400 mg and 200 mg by the subcutaneous route, respectively) continued to provide adequate pain relief after 13 months of therapy despite signs of progressive disease.
-
Anesthesia and analgesia · Oct 1995
Randomized Controlled Trial Clinical TrialSystemic adenosine infusion alleviates spontaneous and stimulus evoked pain in patients with peripheral neuropathic pain.
In seven patients with peripheral neuropathic pain, the effect of systemic adenosine infusion on pain symptoms was evaluated in a double-blind, placebo controlled, cross-over study. The study infusions, adenosine (50 micrograms.kg-1.min-1) or placebo, were given intravenously (IV) during 45-60 min at two separate occasions. Before and during infusions, bedside examination of sensibility and quantitative sensory testing (QST), i.e., assessments of perception thresholds for touch, touch-evoked pain, cold, warmth, painful heat, and cold, were performed. ⋯ Pinprick-evoked pain in the neuropathic areas was reduced from 53 +/- 11 to 29 +/- 10 mm (P < 0.05). No other sensory modality was consistently changed during adenosine infusion. In conclusion, the present study demonstrates that adenosine infusion alleviates spontaneous neuropathic pain, tactile allodynia, and pinprick hyperalgesia in patients with peripheral neuropathic disorders, probably by a central mechanism of action.
-
Review Comparative Study
Topical capsaicin. A review of its pharmacological properties and therapeutic potential in post-herpetic neuralgia, diabetic neuropathy and osteoarthritis.
Capsaicin, the active principle of hot chili pepper, is thought to selectively stimulate unmyelinated C fibre afferent neurons and cause the release of substance P. Prolonged application of capsaicin reversibly depletes stores of substance P, and possibly other neurotransmitters, from sensory nerve endings. This reduces or abolishes the transmission of painful stimuli from the peripheral nerve fibres to the higher centres. ⋯ Topical capsaicin is not associated with any severe systemic adverse effects. However, stinging and burning, particularly during the first week of therapy, is reported by many patients. Topical capsaicin merits consideration as adjuvant therapy in conditions such as post-herpetic neuralgia, diabetic neuropathy and osteoarthritis, where the pain can be chronic and difficult to treat.
-
Clinical Trial Controlled Clinical Trial
Effects of regional intravenous guanethidine in patients with neuralgia in the hand; a follow-up study over a decade.
A study on the effect of regional intravenous (i.v.) guanethidine blockade (RGB) was done over a 10 years period in patients with post-traumatic neuralgia. Seven patients, investigated with quantitative sensory testing (QST) before and after RGB between 1979 and 1982, were reinvestigated in the period 1990-1992. In addition to the RGB, 6 patients were subjected to a placebo procedure with tourniquet inflation and i.v. injection of saline at follow-up. ⋯ RGB, whereas others consistently had no such effect. None obtained long-lasting pain relief from placebo. This supports the notion that different pathophysiological mechanisms are involved in post-traumatic neuralgia.